GA
TRIB

Geneva Advisors’s Trinity Biotech TRIB Stock Holding History

Geneva Advisors’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-248
Closed -$491K – 807
2016
Q3 		$491K Sell
248
-2
-0.8% -$3.73K 0.01% 470
2016
Q2 		$425K Sell
250
-151
-38% -$255K 0.01% 477
2016
Q1 		$702K Hold
401
– – 0.01% 361
2015
Q4 		$707K Sell
401
-871
-68% -$1.54M 0.01% 360
2015
Q3 		$2.18M Buy
1,272
+71
+6% +$171K 0.04% 182
2015
Q2 		$3.25M Buy
1,201
+168
+16% +$436K 0.06% 160
2015
Q1 		$2.98M Sell
1,033
-117
-10% -$324K 0.05% 167
2014
Q4 		$3.02M Sell
1,150
-40
-3% -$103K 0.06% 165
2014
Q3 		$3.26M Sell
1,190
-9
-0.8% -$29.2K 0.06% 163
2014
Q2 		$4.14M Buy
1,199
+12
+1% +$42.7K 0.08% 143
2014
Q1 		$4.31M Buy
1,187
+251
+27% +$987K 0.08% 134
2013
Q4 		$3.53M Buy
936
+116
+14% +$418K 0.07% 131
2013
Q3 		$2.68M Buy
820
+132
+19% +$386K 0.06% 148
2013
Q2 		$1.74M Buy
+688
New +$1.71M 0.04% 156

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Geneva Advisors's TRIB Position: Q4 2016 in Review

Geneva Advisors sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 248 shares — an estimated $491K sold.

Geneva Advisors first reported a position in TRIB in Q2 2013 and held it in 14 quarters. The position peaked at $4.31M in Q1 2014. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

  • Geneva Advisors reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
  • Geneva Advisors sold 248 Trinity Biotech shares in Q4 2016, an estimated $491K.
  • Geneva Advisors first reported a position in Trinity Biotech in Q2 2013 and held it in 14 quarters.
  • Geneva Advisors's Trinity Biotech position peaked at $4.31M in Q1 2014.
  • 71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on Geneva Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.